Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[tykundegex]

Agreed, not very enlightening for those of us eager to learn of their plans for KIT-302. I thought I caught them saying something about their "out-licensing strategy" when referring to 302 -- anyone else catch that? Is that the first time we hear specifically that they're not seeking to sell the asset outright?

The news on the oncology acquisition was very encouraging IMO, and they clearly have a finely-tuned idea of how they want to commercialize this drug. But it's not going to lead to any near-term events which could cause an up-tick in the share price, I'm afraid.